Warning letter
New Life Pharma LLC: warning letter of Apr 14, 2026
FDA warning letter 725661 · Center for Drug Evaluation and Research (CDER)
Key facts
| Reference number | 725661 |
|---|---|
| Company | New Life Pharma LLC |
| Subject | CGMP/Adulterated and Unapproved New Drug/Misbranded |
| Issue date | Apr 14, 2026 |
| Posted date | Apr 21, 2026 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| Product type | Drugs |
| CFR sections cited | 211.84(d)(1), 211.137(a), 201.128, 211.167(a), 207.25(f), 207.41, 207.77(c), 211.22, 211.113(b), 211.100(a) |
| Inspection city | Northvale |
| Inspection ZIP | 07647-1901 |
| Inspection start date | Feb 3, 2026 |
| Letter on fda.gov | fda.gov |
At a glance
- 10–99 CFR sections cited
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: